Related Experiment Video
Updated: Jul 8, 2025
Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
Published on: May 9, 2022
CCR2 is a potential therapeutic target in peri-implantitis
Shasha Yuan1,2, Yiping Wei1, Wenting Jiang1
1Department of Periodontology, National Clinical Research Center for Oral Diseases, National Engineering Laboratory for Digital and Material Technology of Stomatology, Beijing Key Laboratory of Digital Stomatology, Peking University School and Hospital of Stomatology, Beijing, China.
Aim:
CCR2 (C-C chemokine receptor type 2) plays a crucial role in inflammatory and bone metabolic diseases; however, its role in peri-implantitis remains unclear. This study aimed to explore whether CCR2 contributes to peri-implantitis and the treatment effects of cenicriviroc (CVC) on peri-implant inflammation and bone resorption.
Materials And Methods:
The expression of CCR2 was studied using clinical tissue analysis and an in vivo peri-implantitis model. The role of CCR2 in promoting inflammation and bone resorption in peri-implantitis was evaluated in Ccr2-/- mice and wild-type mice. The effect of CVC on peri-implantitis was evaluated using systemic and local dosage forms.
Results:
Human peri-implantitis tissues showed increased CCR2 and CCL2 levels, which were positively correlated with bone loss around the implants. Knocking out Ccr2 in an experimental model of peri-implantitis resulted in decreased monocyte and macrophage infiltration, reduced pro-inflammatory cytokine generation and impaired osteoclast activity, leading to reduced inflammation and bone loss around the implants. Treatment with CVC ameliorated bone loss in experimental peri-implantitis.
Conclusions:
CCR2 may be a potential target for peri-implantitis treatment by harnessing the immune-inflammatory response to modulate the local inflammation and osteoclast activity.
Insights
C-C chemokine receptor type 2 (CCR2) drives peri-implantitis by promoting inflammation and bone loss. Blocking CCR2 with cenicriviroc (CVC) reduced these effects, suggesting CCR2 as a therapeutic target for peri-implantitis.
Area of Science:
- Immunology
- Oral Biology
- Pharmacology
Background:
- Peri-implantitis involves inflammation and bone loss around dental implants.
- The role of C-C chemokine receptor type 2 (CCR2) in peri-implantitis pathogenesis is not well understood.
Purpose of the Study:
- To investigate the contribution of CCR2 to peri-implantitis.
- To evaluate the therapeutic potential of cenicriviroc (CVC) in treating peri-implantitis.
Main Methods:
- Analysis of CCR2 expression in human peri-implantitis tissues.
- Utilizing an in vivo peri-implantitis model in Ccr2 knockout and wild-type mice.
- Assessing the effects of systemic and local CVC administration.
Main Results:
- Elevated CCR2 and CCL2 levels in human peri-implantitis tissues correlated with bone loss.
- Ccr2 deficiency reduced inflammatory cell infiltration, pro-inflammatory cytokine production, and osteoclast activity.
- CVC treatment mitigated bone loss in experimental peri-implantitis.
Conclusions:
- CCR2 plays a significant role in peri-implantitis by modulating immune-inflammatory responses and osteoclast activity.
- Targeting CCR2 with CVC offers a potential therapeutic strategy for managing peri-implantitis.
